Pharmacoeconomic analysis of thrombopoietin receptor agonists in the treatment of chronic idiopathic thrombocytopenic purpura in adults

Actuallity. Idiopathic thrombocytopenic purpura (ITP) is an autoimmune disease caused by the production of antibodies to the platelet and megakaryocytes membrane structure, which causes to increase the platelet destruction, but also inadequate thrombocytopoiesis. ‹e disease is characterized by a significant loss of ability to work and decreasing quality of life, higher mortality rate, as well as frequent hospitalizations, re­ecting to health care resources utilization. ‹Therefore, burden of disease assessment is a point of high interest. Methodology. Two pharmacoeconomic models were developed for the "cost-minimization" and "budget impact" analysis on the basis of MicrosoŽ Excel soŽware. ‹e modeling hypothesis is comparable efficacy and safety of thrombopoietin receptor agonists (TPO), based on the absence of statistically significant differences from the results of an indirect comparison and the efficacy of romiplostim is assumed to be equal to the efficacy of eltrombopag. Direct medical costs were calculated based on the costs of drugs from the TPO receptor agonist group, the administration of drugs, «rescue therapy», bleeding treatment, and follow-up monitoring of patients with ITP during therapy. Calculations were based on registered limit transfer drug prices from the VED List and standards of the Œfinancial expenses per medical care volume unit of Russian Federation in 2018. ‹e reduction in costs per patient per year is 796,967 rubles (33 %). Results. Clinical and economic analysis of drugs from the group of thrombopoietin receptor agonists in the therapy of chronic idiopathic thrombocytopenic purpura in adults has shown that eltrombopag in comparison with romiplostim in patients with chronic ITP at the background of previous treatment failure is more economically expedient being not less clinical effective. It is possible to reduce the budget impact of the healthcare system of the Russian Federation by 1,693 million rubles (8 %) for 5 years with the gradual increasing in eltrombopag share in the purchase of TPO receptor agonists. Conclusion. Eltrombopag with comparable efficacy and safety is more economically sound option of chronic ITP treatment as compared to romiplostim.

1. Melikyan AL, Pustovaya EN, Cvetaeva NV, et al. Nacional'nye klinicheskie rekomendacii po diagnostike i lecheniyu pervichnoj immunnoj trombocitopenii (idiopaticheskoj trombocitopenicheskoj purpury) u vzroslyh. Gematologiya i transfuziologiya, 2017; 62 (1, pril.1): 1–60. [Melikyan AL, Pustovaya EN, Tsvetaeva NV. in. and other. National clinical guidelines for the diagnosis and treatment of primary immune thrombocytopenia (idiopathic thrombocytopenic purpura) in adults. Hematology & Transfusiology], 2017; 62 (1, approx.1): 1–60. (In Russ)

2. National Institute for Clinical Excellence (NICE). NICE technology appraisal. Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) (TA293). Available at: http://www.nice.org.uk/guidance/ta293

3. Postanovlenie Pravitel'stva Rossijskoj Federacii ot 26 aprelya 2012 g. No 403 g. Moskva "O poryadke vedeniya Federal'nogo registra lic, stradayushchih zhizneugrozhayushchimi i hronicheskimi progressiruyushchimi redkimi (orfannymi) zabolevaniyami, privodyashchimi k sokrashcheniyu prodolzhitel'nosti zhizni grazhdan ili ih invalidnosti, i ego regional'nogo segmenta". [Resolution of the Government of the Russian Federation No 403 of 26 April 2012 "On the procedure for maintaining the Federal register of persons suffering from life-threatening and chronic progressive rare (orphan) diseases, resulting in a reduction in the life expectancy of citizens or their disability, and its regional segment"] (In Russ)

4. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Revolejd. Reg.nomer: LRS-010032/09 - 020615. [Instructions for drug Revolade. Reg.number: LRS-010032/09 - 020615]. Available at: http://grls. rosminzdrav.ru/Grls_View_v2.aspx?idReg=1125929&t=] (In Russ)

5. Instrukciya po primeneniyu lekarstvennogo preparata dlya medicinskogo primeneniya Ehnplejt. Reg.nomer: LRS-007739/09 - 190614. [Instructions for drug Inplete. Reg.number: LRS-007739/09 - 190614]. Available at: http:// grls.rosminzdrav.ru/Grls_View_v2.aspx?idReg=12387&t=] (In Russ)

6. Gosudarstvennyj reestr predel'nyh otpusknyh cen na lekarstvennye preparaty dlya medicinskogo primeneniya. [The state register of maximum ex-works prices for the medicinal products for medical use]. Available at: http:// grls.rosminzdrav.ru/Default.aspx] (In Russ)

7. National Institute for Clinical Excellence (NICE). NICE technology appraisal TA221: Romiplostim for the treatment of chronic immune (idiopathic) thrombocytopenic purpura – Costing template. Available at: http://www.nice. org.uk/resource/ta221/html/p/ta221-thrombocytopenicpurpura-romiplostimcosting-template?id=43356mq3pjhrhxncwqdykxuzqe.

8. National Institute for Clinical Excellence (NICE). NICE technology appraisal TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205) – Costing statement. Available at: http://www.nice.org.uk/resource/ta293/html/p/ta293- thrombocytopenic-purpuraeltrombopag-costing-statement?id=mthd7nqxyap jjqw2c5rfmkayim

9. Cheng G, Saleh MN, Marcher C, Vasey S, Mayer B, Aivado M, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet, 2011; 377: 393–402.

10. Boyers D, Jia X, Jenkinson D, Mowatt G. Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisal. Pharmacoeconomics. 2012; 30 (6): 483–95.

11. Allen R, Brainsky A, Grotzinger K, et al. «A Comment on Boyers et al.: "Eltrombopag for the Treatment of Chronic Immune or Idiopathic Thrombocytopenic Purpura: A NICE Single Technology Appraisal"». PharmacoEconomics. 2013; 31: 1 87–89.

12. Postanovlenie Pravitel'stva RF No1492 ot 8 dekabrya 2017 g. "O Programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2018 god i na planovyj period 2019 i 2020 godov". [Government resolution No 1492 of December 8, 2017 "On the Program of state guarantees of free rendering to citizens medical care for the year 2018 and the planning period of 2019 and 2020"] (In Russ)

13. Federal'naya sluzhba gosudarstvennoj statistiki. Operativnaya informaciya. Ocenka chislennosti postoyannogo naseleniya na 1 yanvarya 2017 goda i v srednem za 2016 god. [Federal state statistics service. Operational information. Estimate the permanent population as of January 1, 2017 and the average for 2016]. Available at: www.gks.ru/wps/wcm/connect/rosstat_main/.../ru/.../ demography/ (In Russ)

14. Federal'naya sluzhba gosudarstvennoj statistiki. Operativnaya informaciya. Raspredelenie naseleniya Rossijskoj Federacii po polu i vozrastnym gruppam (na 1 yanvarya 2017 g.). [Federal state statistics service. Operational information. Distribution of the population of the Russian Federation by sex and age group (as of January 1, 2017)]. Available at: http://www.gks.ru/wps/wcm/connect/ rosstat_main/rosstat/ru/statistics/population/demography/ (In Russ)

15. Saleh MN, Bussel JB, Cheng G, et al. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood, 121.3, (2013), 537–545.

16. Metodicheskie rekomendacii po provedeniyu sravnitel'noj klinikoehkonomicheskoj ocenki lekarstvennogo preparata. Utverzhdeny prikazom FGBU "CEHKKMP" Minzdrava Rossii ot "23" dekabrya 2016 g. No 145-od. [Methodological recommendations for comparative clinical and economic evaluation of the drug. Approved by order FGBU "CEHKKMP" Ministry of health of Russia from 23 December 2016 No. 145-od]. Available at: http:// rosmedex.ru/ocenka-texnologij-zdravooxraneniya/metodicheskierekomendacii/ (In Russ)

17. Metodicheskie rekomendacii po ocenke vliyaniya na byudzhet v ramkah realizacii programmy gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi. Utverzhdeny prikazom FGBU "CEHKKMP"Minzdrava Rossii ot 23 dekabrya 2016 g 145-od. [Methodical recommendations for assessing the impact on the budget as part of the program of state guarantees for free provision of medical care to citizens. Approved by the order FGBU "CEHKKMP" Ministry of Health of Russia from "23" December 2016 No. 145-od.] Available at: http://rosmedex.ru/ocenka-texnologij-zdravooxraneniya/ metodicheskierekomendacii/ (In Russ)

18. Kuter DJ, Bussel JB, Lyons RM, Pullarkat V, Gernsheimer TB, Senecal FM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomized controlled trial. Lancet, 2008; 371 (9610): 395–403.

19. Postanovlenie Pravitel'stva RF ot 8 dekabrya 2017 g. No 1492 "On programme gosudarstvennyh garantij besplatnogo okazaniya grazhdanam medicinskoj pomoshchi na 2018 god i na planovyj period 2019 i 2020 godov". [Resolution of the government of the Russian Federation of December 8, 2017 No 1492 "O the program of state guarantees of free medical care for citizens in 2018 and the planning period 2019 and 2020 years"]. Available at: http://www. garant.ru/hotlaw/federal/1154371/ (In Russ)

20. Rasporyazhenie Pravitel'stva RF ot 23.10.2017 g. No 2323-r "Ob utverzhdenii perechnya zhiznenno neobhodimyh i vazhnejshih lekarstvennyh preparatov na 2018 god, a takzhe perechnej lekarstvennyh preparatov dlya medicinskogo primeneniya i minimal'nogo assortimenta lekarstvennyh preparatov, neobhodimyh dlya okazaniya medicinskoj pomoshchi". [Order of the government of the Russian Federation No 2323-R of 23.10.2017 "Оn approval of the list of vital and essential medicines for 2018, as well as lists of medicines for medical application and the minimum assortment of medicinal preparations necessary for rendering medical care"] (In Russ)